Skip to content
Biotech Intelligence

Beijing Mabworks Biotech Co., Ltd.

biotechChina
Trials
0
Subs
0
People
0
Links
0

Executive Summary

AI synthesis

Beijing Mabworks Biotech is a Chinese biotech company with limited publicly available information, presenting significant due diligence challenges for US BD teams. The company appears to focus on biologics development based on its name, but pipeline details, leadership, and corporate structure remain opaque. BIOSECURE risk appears low based on current designation status, though the lack of transparency warrants careful evaluation.

Structure: Corporate structure details are not publicly available, which is unusual for a company actively seeking partnerships. The absence of subsidiary information and key personnel data suggests either a very early-stage company or limited disclosure practices that would require extensive due diligence.

BIOSECURE Risk

low

Currently designated as clear under BIOSECURE with no BCC designation, suggesting no immediate regulatory restrictions

Key Exposures:

  • •Limited public disclosure may hide potential restricted relationships
  • •Chinese biotech sector subject to ongoing BIOSECURE scrutiny

Mitigation: No specific mitigation efforts publicly documented due to limited available information

BD Intelligence

Pipeline Strength3/10
Deal Readiness2/10

Therapeutic Areas:

Unknown - likely biologics/antibodies based on company name

Recent Deals: No recent deal activity identified in available records

Approach: Proceed with extreme caution - request comprehensive corporate disclosure package before any meaningful discussions. Consider this a high due diligence risk opportunity.

Red Flags

  • ⚠Complete absence of key personnel information
  • ⚠No publicly available pipeline or technology details
  • ⚠Lack of subsidiary or corporate structure transparency
  • ⚠No track record of announced partnerships or deals
  • ⚠Insufficient information for standard BD evaluation

Quick Facts

Key People
0
Subsidiaries
0
CDMO/CRO Subs
0
Genomics Subs
0
Direct BIOSECURE
0
Corp Events
0
Gov-Connected
0
Clinical Trials
0
Publications
0
Drug Molecules
0
Relationships
0

Sources & Methodology

Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)

SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)

Publications: Europe PMC API (0 publications indexed)

Drug molecules: ChEMBL database (European Bioinformatics Institute)

Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)

Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures

Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)

Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.